NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
Topline data from pivotal Phase 3 TANDEM trial now expected in 4Q 2024 due to faster than expected enrollment – – On-track to report topline data from pivotal Phase 3 BROADWAY trial in 4Q 2024 – – ...
manilatimes52 分钟
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 ...
Praxis recognized $0.3 million in collaboration revenue during the three months ended September 30, 2024, compared to $0.5 ...